Dermira Inc (NASDAQ:DERM) was the target of some unusual options trading activity on Monday. Investors purchased 4,691 put options on the company. This represents an increase of approximately 681% compared to the average daily volume of 601 put options.
DERM has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $20.00 price target on shares of Dermira and gave the company a “buy” rating in a report on Friday, December 28th. BidaskClub downgraded shares of Dermira from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 15th. Guggenheim reiterated a “buy” rating and issued a $20.00 price target on shares of Dermira in a report on Tuesday, November 20th. Zacks Investment Research raised shares of Dermira from a “hold” rating to a “buy” rating and set a $8.25 price objective on the stock in a research note on Thursday, January 10th. Finally, HC Wainwright began coverage on shares of Dermira in a research note on Thursday, February 14th. They issued a “buy” rating and a $13.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $14.91.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE grew its stake in Dermira by 469.9% in the 4th quarter. Bank of America Corp DE now owns 2,172,328 shares of the biopharmaceutical company’s stock valued at $15,619,000 after acquiring an additional 1,791,178 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Dermira by 2.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 943,421 shares of the biopharmaceutical company’s stock worth $6,783,000 after purchasing an additional 22,816 shares during the last quarter. Sofinnova Investments Inc. boosted its stake in shares of Dermira by 9.5% during the 4th quarter. Sofinnova Investments Inc. now owns 542,224 shares of the biopharmaceutical company’s stock worth $3,899,000 after purchasing an additional 46,931 shares during the last quarter. Sofinnova Ventures Inc boosted its stake in shares of Dermira by 35.9% during the 3rd quarter. Sofinnova Ventures Inc now owns 495,293 shares of the biopharmaceutical company’s stock worth $5,399,000 after purchasing an additional 130,953 shares during the last quarter. Finally, First Midwest Bank Trust Division boosted its stake in shares of Dermira by 31.2% during the 4th quarter. First Midwest Bank Trust Division now owns 443,625 shares of the biopharmaceutical company’s stock worth $3,190,000 after purchasing an additional 105,565 shares during the last quarter. 87.81% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ DERM opened at $14.13 on Wednesday. The stock has a market capitalization of $288.11 million, a P/E ratio of -2.70 and a beta of 1.34. Dermira has a 52 week low of $6.00 and a 52 week high of $14.91. The company has a debt-to-equity ratio of 5.21, a quick ratio of 8.48 and a current ratio of 8.70.
Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Tuesday, February 26th. The biopharmaceutical company reported ($1.70) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.75) by $0.05. Dermira had a negative net margin of 523.25% and a negative return on equity of 224.80%. As a group, equities research analysts expect that Dermira will post -5.43 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2019/03/20/traders-purchase-large-volume-of-dermira-put-options-derm.html.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
Further Reading: Quiet Period Expirations Explained
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.